Subcutaneous pantoprazole in an elderly, palliative care patient

BMJ Support Palliat Care. 2022 Jul;12(e2):e187-e188. doi: 10.1136/bmjspcare-2019-001916. Epub 2019 Aug 28.

Abstract

Proton pump inhibitors (PPIs) have become the agents of choice for acid-related diseases. In some clinical situations, PPI therapy by oral or intravenous route may be difficult especially among elderly and patients in palliative care. Off-label PPI subcutaneous injection could be the last alternative to improve patient relief, despite limited published data. We report a case of linitis plastica, peritoneal carcinomatosis and occlusive syndrome who suffered from painful regurgitations which rapidly improved after subcutaneous pantoprazole. No related adverse effects were observed during PPI therapy. Despite some limitations, this report suggests that off-label subcutaneous pantoprazole could be an interesting alternative route when intravenous infusion may be difficult or harmful for elderly and patients in palliative care. Nevertheless, clinical safety and efficiency data on larger populations are needed to validate this use in such population.

Keywords: geriatrics; palliative care; pantoprazole; proton pump inhibitor; subcutaneous route.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Humans
  • Palliative Care*
  • Pantoprazole / therapeutic use
  • Proton Pump Inhibitors* / therapeutic use

Substances

  • Proton Pump Inhibitors
  • Pantoprazole